These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 31393852)

  • 1. Adipocyte JAK2 mediates spontaneous metabolic liver disease and hepatocellular carcinoma.
    Corbit KC; Wilson CG; Lowe D; Tran JL; Vera NB; Clasquin M; Mattis AN; Weiss EJ
    JCI Insight; 2019 Aug; 5(17):. PubMed ID: 31393852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adipocyte JAK2 Regulates Hepatic Insulin Sensitivity Independently of Body Composition, Liver Lipid Content, and Hepatic Insulin Signaling.
    Corbit KC; Camporez JPG; Edmunds LR; Tran JL; Vera NB; Erion DM; Deo RC; Perry RJ; Shulman GI; Jurczak MJ; Weiss EJ
    Diabetes; 2018 Feb; 67(2):208-221. PubMed ID: 29203511
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disruption of JAK2 in adipocytes impairs lipolysis and improves fatty liver in mice with elevated GH.
    Nordstrom SM; Tran JL; Sos BC; Wagner KU; Weiss EJ
    Mol Endocrinol; 2013 Aug; 27(8):1333-42. PubMed ID: 23782652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice.
    Shi SY; Luk CT; Schroer SA; Kim MJ; Dodington DW; Sivasubramaniyam T; Lin L; Cai EP; Lu SY; Wagner KU; Bazinet RP; Woo M
    J Biol Chem; 2017 Mar; 292(9):3789-3799. PubMed ID: 28100771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic growth hormone - JAK2 - STAT5 signalling: Metabolic function, non-alcoholic fatty liver disease and hepatocellular carcinoma progression.
    Kaltenecker D; Themanns M; Mueller KM; Spirk K; Suske T; Merkel O; Kenner L; Luís A; Kozlov A; Haybaeck J; Müller M; Han X; Moriggl R
    Cytokine; 2019 Dec; 124():154569. PubMed ID: 30389231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.
    Attia YM; Tawfiq RA; Gibriel AA; Ali AA; Kassem DH; Hammam OA; Elmazar MM
    Biochem Pharmacol; 2021 Apr; 186():114497. PubMed ID: 33675775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adipocyte JAK2 mediates growth hormone-induced hepatic insulin resistance.
    Corbit KC; Camporez JPG; Tran JL; Wilson CG; Lowe DA; Nordstrom SM; Ganeshan K; Perry RJ; Shulman GI; Jurczak MJ; Weiss EJ
    JCI Insight; 2017 Feb; 2(3):e91001. PubMed ID: 28194444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
    Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NIK/MAP3K14 in hepatocytes orchestrates NASH to hepatocellular carcinoma progression via JAK2/STAT5 inhibition.
    Vesting AJ; Jais A; Klemm P; Steuernagel L; Wienand P; Fog-Tonnesen M; Hvid H; Schumacher AL; Kukat C; Nolte H; Georgomanolis T; Altmüller J; Pasparakis M; Schmidt A; Krüger M; Supprian MS; Waisman A; Straub BK; Raschzok N; Bernier M; Birkenfeld AL; Hövelmeyer N; Brüning JC; Wunderlich FT
    Mol Metab; 2022 Dec; 66():101626. PubMed ID: 36356831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth-hormone-induced signal transducer and activator of transcription 5 signaling causes gigantism, inflammation, and premature death but protects mice from aggressive liver cancer.
    Friedbichler K; Themanns M; Mueller KM; Schlederer M; Kornfeld JW; Terracciano LM; Kozlov AV; Haindl S; Kenner L; Kolbe T; Mueller M; Snibson KJ; Heim MH; Moriggl R
    Hepatology; 2012 Mar; 55(3):941-52. PubMed ID: 22031092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic effects of reduced growth hormone action in fatty liver disease.
    Rufinatscha K; Ress C; Folie S; Haas S; Salzmann K; Moser P; Dobner J; Weiss G; Iruzubieta P; Arias-Loste MT; Crespo J; Tilg H; Kaser S
    Hepatol Int; 2018 Sep; 12(5):474-481. PubMed ID: 30206761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adult-Onset Hepatocyte GH Resistance Promotes NASH in Male Mice, Without Severe Systemic Metabolic Dysfunction.
    Cordoba-Chacon J; Sarmento-Cabral A; Del Rio-Moreno M; Diaz-Ruiz A; Subbaiah PV; Kineman RD
    Endocrinology; 2018 Nov; 159(11):3761-3774. PubMed ID: 30295789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis.
    Mukherjee S; Chakraborty M; Ulmasov B; McCommis K; Zhang J; Carpenter D; Msengi EN; Haubner J; Guo C; Pike DP; Ghoshal S; Ford DA; Neuschwander-Tetri BA; Chakraborty A
    Mol Metab; 2021 Dec; 54():101364. PubMed ID: 34757046
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC.
    Grohmann M; Wiede F; Dodd GT; Gurzov EN; Ooi GJ; Butt T; Rasmiena AA; Kaur S; Gulati T; Goh PK; Treloar AE; Archer S; Brown WA; Muller M; Watt MJ; Ohara O; McLean CA; Tiganis T
    Cell; 2018 Nov; 175(5):1289-1306.e20. PubMed ID: 30454647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment.
    Agosti P; Sabbà C; Mazzocca A
    Biochim Biophys Acta Mol Basis Dis; 2018 Feb; 1864(2):607-617. PubMed ID: 29197664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisomal β-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease.
    Moreno-Fernandez ME; Giles DA; Stankiewicz TE; Sheridan R; Karns R; Cappelletti M; Lampe K; Mukherjee R; Sina C; Sallese A; Bridges JP; Hogan SP; Aronow BJ; Hoebe K; Divanovic S
    JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of FGF21 promotes NASH-HCC transition
    Zheng Q; Martin RC; Shi X; Pandit H; Yu Y; Liu X; Guo W; Tan M; Bai O; Meng X; Li Y
    Theranostics; 2020; 10(22):9923-9936. PubMed ID: 32929325
    [No Abstract]   [Full Text] [Related]  

  • 19. Aberrant FGFR4 signaling worsens nonalcoholic steatohepatitis in FGF21KO mice.
    Yu Y; Shi X; Zheng Q; Wang X; Liu X; Tan M; Lv G; Zhang P; Martin RC; Li Y
    Int J Biol Sci; 2021; 17(10):2576-2589. PubMed ID: 34326695
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatocellular carcinoma in a mouse model fed a choline-deficient, L-amino acid-defined, high-fat diet.
    Ikawa-Yoshida A; Matsuo S; Kato A; Ohmori Y; Higashida A; Kaneko E; Matsumoto M
    Int J Exp Pathol; 2017 Aug; 98(4):221-233. PubMed ID: 28895242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.